Compare AERT & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | ACXP |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 6.2M |
| IPO Year | 2021 | 2021 |
| Metric | AERT | ACXP |
|---|---|---|
| Price | $6.81 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | 16.0K | ★ 76.9K |
| Earning Date | 02-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.87 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $70,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $1.31 |
| 52 Week High | $7.65 | $8.34 |
| Indicator | AERT | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 45.79 |
| Support Level | $6.53 | $1.33 |
| Resistance Level | $7.30 | $1.46 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 25.01 | 40.00 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs. It has more than 40 clients spanning across industry segments.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.